ClinicalTrials.gg
CompletedNCT00678535EXPANDUpdated Jul 21, 2014Results posted

Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer

A Phase 3 interventional study of Cetuximab and Capecitabine in Gastric Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 130 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-21.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
904
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing cetuximab in Stomach Neoplasms — none open to participants now, none under way, none of them phase 3. Cetuximab · Stomach Neoplasms.

Enrollment
Largest of 17
904 · median 41
Started
2008
with 1 other
Phase 3
Only one
of the 17
Registered
11th of 17
by date
Lead sponsor
2 of 17
Merck KGaA, Darmstadt, Germany

Among the 17 studies testing cetuximab in Stomach Neoplasms, this one has the largest enrollment, is one of 2 that started in 2008, is the only one in phase 3, and was the 11th registered.

Stomach Neoplasms

3,401 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

None of the 17 studies testing cetuximab in Stomach Neoplasms is open now. The open studies under Stomach Neoplasms, anywhere →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing cetuximab in Stomach Neoplasms as a file.
02

Study summary

The primary objective of this study is to demonstrate that addition of cetuximab to 1st-line treatment with capecitabine (Xeloda, X) and cisplatin (P) [XP] chemotherapy regimen has a clinically relevant benefit for subjects with advanced gastric adenocarcinoma including gastroesophageal junction (GEJ) adenocarcinoma, in terms of progression free survival (PFS).

Secondary objectives are to assess cetuximab plus XP versus XP alone with respect to overall survival, overall tumor response, quality of life (QoL) and safety.

03

Conditions studied

  • Gastric Cancer

Browse trials for

Keywords

  • 1st line treatment for Gastric Cancer
  • Cetuximab
  • Capecitabine
  • Xeloda
  • Cisplatin
  • Progression-free survival
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written before any study-related activities are carried out
  • Age greater than or equal to (>=) 18 years
  • confirmed adenocarcinoma of the stomach or gastroesophageal junction (Adenocarcinoma of the gastroesophageal junction [AEG] Types I-III according to Siewert classification)
  • Archived tumor material sample for at least subsequent standardized Epidermal Growth Factor Receptor (EGFR) expression assessment
  • Unresectable advanced (M0) or unresectable (M1) disease
  • At least one radiographically documented in a previously non-irradiated area according to (RECIST). The primary tumor site is to be considered as a non-measurable lesion only
  • (ECOG) performance status 0-1
  • Estimated greater than (>) 12 weeks
  • Medically accepted (if the risk of conception exists)
  • (GFR) >= 60 milliliter per minute (mL/min) The GFR is based on the formula for creatinine clearance
  • Aspartate-aminotransferase (ASAT) less than or equal to (=\<) 2.5 * (ULN) and alanine-aminotransferase (ALAT) =\< 2.5 *ULN
  • =\< 3 * ULN
  • (ANC) >= 1.5 * 10\^9 per liter
  • >= 100 * 10\^9 per liter
  • >=10 gram per deciliter (g/dL) (without transfusions)
  • Sodium and potassium within normal limits or =\< 10 percent above or below (supplementation permitted)

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy, however, previous (neo-) (radio-) chemotherapy allowed if finished > 1 year prior to start of study treatment and no more than 300 mg/m\^2 cisplatin has been administered
  • Prior treatment with an antibody or molecule targeting EGFR and/or Vascular Endothelial Growth Factor Receptor (VEGFR) related signaling pathways
  • and/or (known or suspected)
  • Radiotherapy (except localized radiotherapy for pain relief), major surgery or any drug within 30 days before the start of study treatment
  • Concurrent chronic systemic immune or hormone therapy not indicated in this study protocol (except for physiologic replacement)
  • coronary artery disease ( [NYHA] functional angina classification III/IV), congestive heart failure (NYHA III/IV), clinically relevant cardiomyopathy, history of myocardial infarction in the 12 months before study Screening, or high risk of uncontrolled arrhythmia
  • Active or C
  • Chronic diarrhea or short bowel syndrome
  • Presence of any to treatment with cetuximab, capecitabine and cisplatin including:

    • Known to capecitabine, fluorouracil, cisplatin, cetuximab or to any of the of these drugs
    • Known dihydropyrimidine dehydrogenase (DPD) deficiency
    • Hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
    • Current treatment with sorivudine or chemically related analogues, such as brivudine
    • Symptomatic peripheral neuropathy National Cancer Institute - (NCI-CTCAE) Grade >= 2 and/or ototoxicity NCI CTCAE Grade >= 2, except if due to trauma or mechanical impairment due to tumor mass
  • Pregnancy or lactation period
  • Concurrent treatment with a non-permitted drug
  • Treatment in another clinical study within 30 days prior to study screening
  • Previous other than gastric cancer within 5 years prior to study screening, except for basal cell cancer of the skin or pre-invasive cancer of the cervix
  • Medical or psychological conditions that would not permit the subject to complete the study or sign
  • Legal incapacity or limited legal capacity
  • Significant disease which, in the Investigator's opinion, would exclude the subject from the study
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
904 participants (actual)

Study arms

  • Experimental
    Cetuximab plus Capecitabine plus Cisplatin

    Drug: Cetuximab · Drug: Capecitabine · Drug: Cisplatin

  • Active comparator
    Capecitabine plus Cisplatin

    Drug: Capecitabine · Drug: Cisplatin

Interventions

  • Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m\^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.

    Also known as: Erbitux

  • Capecitabine 1000 mg/m\^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.

    Also known as: Xeloda

  • Cisplatin 80 mg/m\^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments

    The PFS time is defined as the duration from randomization to either first observation of progressive disease (PD) or occurrence of death due to any cause within 60 days of the last tumor assessment or randomization. Participants without event are censored on the date of last tumor assessment.

    Time frame: Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)

Secondary outcomes

  1. Overall Survival (OS)

    The OS time is defined as the time from randomization to death or last day known to be alive. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.

    Time frame: Time from randomization to death or last day known to be alive, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date, (31 Mar 2012)

  2. Best Overall Response (BOR) Rate: Independent Review Committee (IRC) Assessments

    The BOR rate is defined as the percentage of participants having achieved complete response (CR) or partial response (PR) as the best overall response, based on radiological assessments (based on response evaluation criteria in solid tumors \[RECIST\] Version 1.0) from the IRC.

    Time frame: Every 6 weeks until progression, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date, (31 Mar 2012)

  3. Quality of Life (QoL) Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    Mean global health status and social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.

    Time frame: Baseline, Week 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)

  4. Quality of Life (QoL) Assessed by EuroQol 5Dimensions (EQ-5D) Questionnaire

    EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 single items are combined to obtain a single index score that is health utility index (HUI) score reflecting subject's preferences for different health states. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QoL.

    Time frame: Baseline, Week 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)

  5. Safety - Number of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an investigational medicinal product (IMP), regardless of causal relationship and even if no IMP has been administered.

    Time frame: Time from first dose up to Day 30 after last dose of study treatment, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)

07

Results

Posted May 16, 2013

Participant flow

First/last participant (informed consent): June 2008/December 2010. Clinical data cut-off: 31 March 2012 Study completion 17 February 2013.

Participant flow — Overall Study
MilestoneCetuximab Plus Capecitabine Plus CisplatinCapecitabine Plus Cisplatin
Started455449
Completed362351
Not completed9398

Outcome measures

PrimaryProgression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments

The PFS time is defined as the duration from randomization to either first observation of progressive disease (PD) or occurrence of death due to any cause within 60 days of the last tumor assessment or randomization. Participants without event are censored on the date of last tumor assessment.

Time frame:
Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)
Reported as:
Median · months
Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments
monthsCetuximab Plus Capecitabine Plus CisplatinCapecitabine Plus Cisplatin
Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments4.4 (4.2 to 5.5)5.6 (5.1 to 5.7)
Statistical analysis
  • Cetuximab Plus Capecitabine Plus Cisplatin vs Capecitabine Plus Cisplatin · Stratified log rank · p = 0.3158 · Hazard ratio (hr): 1.091 · 95% CI 0.920 to 1.292Kaplan-Meier method was used to estimate median PFS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.
SecondaryOverall Survival (OS)

The OS time is defined as the time from randomization to death or last day known to be alive. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.

Time frame:
Time from randomization to death or last day known to be alive, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date, (31 Mar 2012)
Reported as:
Median · months
Overall Survival (OS)
monthsCetuximab Plus Capecitabine Plus CisplatinCapecitabine Plus Cisplatin
Overall Survival (OS)9.4 (8.3 to 10.6)10.7 (9.4 to 11.3)
Statistical analysis
  • Cetuximab Plus Capecitabine Plus Cisplatin vs Capecitabine Plus Cisplatin · Stratified log rank · p = 0.9547 · Hazard ratio (hr): 1.004 · 95% CI 0.866 to 1.165Kaplan-Meier method was used to estimate median OS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.
SecondaryBest Overall Response (BOR) Rate: Independent Review Committee (IRC) Assessments

The BOR rate is defined as the percentage of participants having achieved complete response (CR) or partial response (PR) as the best overall response, based on radiological assessments (based on response evaluation criteria in solid tumors \[RECIST\] Version 1.0) from the IRC.

Time frame:
Every 6 weeks until progression, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date, (31 Mar 2012)
Reported as:
Number · percentage of participants
Best Overall Response (BOR) Rate: Independent Review Committee (IRC) Assessments
percentage of participantsCetuximab Plus Capecitabine Plus CisplatinCapecitabine Plus Cisplatin
Best Overall Response (BOR) Rate: Independent Review Committee (IRC) Assessments29.9 (25.7 to 34.3)29.2 (25.0 to 33.6)
Statistical analysis
  • Cetuximab Plus Capecitabine Plus Cisplatin vs Capecitabine Plus Cisplatin · Cochran-Mantel-Haenszel · p = 0.7696 · Odds ratio (or): 1.0435 · 95% CI 0.7844 to 1.3882
SecondaryQuality of Life (QoL) Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

Mean global health status and social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.

Time frame:
Baseline, Week 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)
Reported as:
Mean · units on a scale
Quality of Life (QoL) Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
units on a scaleCetuximab Plus Capecitabine Plus CisplatinCapecitabine Plus Cisplatin
Global health status: Baseline57.49 ± 22.16857.19 ± 22.124
Global health status: Week 659.00 ± 21.87961.80 ± 22.089
Global health status: Week 1260.17 ± 20.79663.35 ± 22.077
Global health status: Week 1860.45 ± 20.01561.83 ± 21.499
Global health status: Week 2462.46 ± 22.97863.61 ± 19.477
Global health status: Week 3063.65 ± 21.72264.11 ± 19.757
Global health status: Week 3665.06 ± 22.62957.72 ± 21.602
Global health status: Week 4259.29 ± 21.55862.64 ± 22.005
Global health status: Week 4863.39 ± 21.31766.67 ± 19.395
Global health status: Week 5460.63 ± 16.19866.67 ± 14.651
Global health status: Week 6062.50 ± 13.91861.81 ± 17.210
Social functioning status: Baseline74.36 ± 27.07776.52 ± 26.601
Social functioning status: Week 668.94 ± 28.88575.70 ± 27.415
Social functioning status: Week 1271.48 ± 26.54775.65 ± 27.691
Social functioning status: Week 1871.22 ± 25.31775.51 ± 25.612
Social functioning status: Week 2474.20 ± 26.14378.26 ± 27.633
Social functioning status: Week 3078.51 ± 24.76676.67 ± 24.962
Social functioning status: Week 3676.28 ± 21.73073.58 ± 22.353
Social functioning status: Week 4268.57 ± 27.34878.16 ± 22.318
Social functioning status at Week 4880.36 ± 22.70578.00 ± 23.432
Social functioning status: Week 5474.71 ± 27.68280.56 ± 27.371
Social functioning status: Week 6078.33 ± 23.63268.06 ± 32.144
SecondaryQuality of Life (QoL) Assessed by EuroQol 5Dimensions (EQ-5D) Questionnaire

EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 single items are combined to obtain a single index score that is health utility index (HUI) score reflecting subject's preferences for different health states. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QoL.

Time frame:
Baseline, Week 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)
Reported as:
Mean · units on a scale
Quality of Life (QoL) Assessed by EuroQol 5Dimensions (EQ-5D) Questionnaire
units on a scaleCetuximab Plus Capecitabine Plus CisplatinCapecitabine Plus Cisplatin
Baseline0.743 ± 0.2400.749 ± 0.235
Week 60.739 ± 0.2760.769 ± 0.254
Week 120.752 ± 0.2390.775 ± 0.246
Week 180.742 ± 0.2510.755 ± 0.235
Week 240.733 ± 0.3000.761 ± 0.265
Week 300.737 ± 0.3010.790 ± 0.230
Week 360.710 ± 0.3110.711 ± 0.309
Week 420.722 ± 0.2090.689 ± 0.307
Week 480.719 ± 0.2270.770 ± 0.216
Week 540.733 ± 0.2750.730 ± 0.191
Week 600.760 ± 0.3220.742 ± 0.170
SecondarySafety - Number of Participants With Adverse Events (AEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an investigational medicinal product (IMP), regardless of causal relationship and even if no IMP has been administered.

Time frame:
Time from first dose up to Day 30 after last dose of study treatment, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)
Reported as:
Number · participants
Safety - Number of Participants With Adverse Events (AEs)
participantsCetuximab Plus Capecitabine Plus CisplatinCapecitabine Plus Cisplatin
Safety - Number of Participants With Adverse Events (AEs)446432

Adverse events

Collected over Time from first dose up to 30 days after the last dose of study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab Plus Capecitabine Plus Cisplatin—239/446 (53.6%)441/446 (98.9%)
Capecitabine Plus Cisplatin—194/436 (44.5%)429/436 (98.4%)
Most frequent serious events
Showing 10 of 236
Most frequent serious events
EventCetuximab Plus Capecitabine Plus CisplatinCapecitabine Plus Cisplatin
Pulmonary embolismRespiratory, thoracic and mediastinal disorders26/44613/436
VomitingGastrointestinal disorders16/44625/436
AnaemiaBlood and lymphatic system disorders10/44617/436
DiarrhoeaGastrointestinal disorders15/44615/436
DehydrationMetabolism and nutrition disorders9/44615/436
Decreased appetiteMetabolism and nutrition disorders15/4463/436
NeutropeniaBlood and lymphatic system disorders9/44613/436
NauseaGastrointestinal disorders11/44613/436
General physical health deteriorationGeneral disorders12/44613/436
FatigueGeneral disorders11/4465/436
Most frequent other events
Showing 10 of 56
Most frequent other events
EventCetuximab Plus Capecitabine Plus CisplatinCapecitabine Plus Cisplatin
NauseaGastrointestinal disorders273/446265/436
NeutropeniaBlood and lymphatic system disorders194/446234/436
Decreased appetiteMetabolism and nutrition disorders221/446201/436
VomitingGastrointestinal disorders165/446192/436
RashSkin and subcutaneous tissue disorders194/44623/436
FatigueGeneral disorders187/446162/436
DiarrhoeaGastrointestinal disorders172/446105/436
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders162/44697/436
AnaemiaBlood and lymphatic system disorders127/446155/436
HypomagnesaemiaMetabolism and nutrition disorders133/44660/436

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cetuximab Plus Capecitabine Plus CisplatinCapecitabine Plus CisplatinTotal
Mean58.0 ± 11.1658.5 ± 10.8358.3 ± 11.00
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab Plus Capecitabine Plus CisplatinCapecitabine Plus CisplatinTotal
Female116115231
Male339334673
08

Study locations

130 sites
  • Research site
    Rosario, Argentina
  • Research site
    Coburg VIC, Australia
  • Research site
    Frankston, VIC, Australia
  • Research site
    Perth, Australia
  • Research site
    Graz, Austria
  • Research site
    Kufstein, Austria
  • Research site
    Steyr, Austria
  • Research Site
    Wien, Austria
  • Research Site
    Zams, Austria
  • Research Site
    Bonheiden, Belgium
  • Research Site
    Bruxelles, Belgium
  • Research site
    Verviers, Belgium
  • Research site
    Campinas, Brazil
  • Research site
    Ijui, Brazil
  • Research site
    Jaú, Brazil
  • Research site
    Porto Alegre, Brazil
  • Research site
    Salvador, Brazil
  • Research site
    Santo André, Brazil
  • Research site
    Sâo Paulo, Brazil
  • Research site
    Pleven, Bulgaria
  • Research site
    Plovdiv, Bulgaria
  • Research site
    Rousse, Bulgaria
  • Research site
    Sofia, Bulgaria
  • Research site
    Reñaca, Chile
  • Research site
    Santiago, Chile
  • Research site
    Temuco, Chile
  • Research site
    Valparaiso, Chile
  • Research site
    Beijing, China
  • Research site
    Guangzhou, China
  • Research site
    Hefei, China
  • Research site
    Nanjing, China
  • Research site
    Shanghai, China
  • Research site
    Shenyang, China
  • Research Site
    Brno, Czech Republic
  • Research Site
    Hradec Králové, Czech Republic
  • Research site
    Prague 5, Czech Republic
  • Research site
    Besancon, France
  • Research site
    Clermont Ferrand Cedex 1, France
  • Research site
    La Roche sur Yon, France
  • Research site
    Marseille, France
  • Research site
    Paris 14, France
  • Research site
    Rennes, France
  • Research Site
    Berlin, Germany
  • Research site
    Bielefeld, Germany
  • Research site
    Braunschweig, Germany
  • Research Site
    Dresden, Germany
  • Research Site
    Essen, Germany
  • Research site
    Esslingen, Germany
  • Research site
    Frankfurt, Germany
  • Research Site
    Giessen, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Heidelberg, Germany
  • Research site
    Köln, Germany
  • Research site
    Ludwigshafen, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    München, Germany
  • Research site
    Offenbach, Germany
  • Research Site
    Regensburg, Germany
  • Research site
    Schweinfurt, Germany
  • Research Site
    Schwäbisch Hall, Germany
  • Research site
    Stuttgart, Germany
  • Research Site
    Timisoara, Germany
  • Research Site
    Troisdorf, Germany
  • Research site
    Ulm, Germany
  • Research site
    Weiden, Germany
  • Research Site
    Weilheim, Germany
  • Research site
    Ioannina, Greece
  • Research site
    Thessaloniki, Greece
  • Research site
    Hong Kong, Hong Kong
  • Research site
    Budapest, Hungary
  • Research site
    Gyor, Hungary
  • Research Site
    Kaposvar, Hungary
  • Research Site
    Tatabanya, Hungary
  • Research site
    Haifa, Israel
  • Research site
    Jerusalem, Israel
  • Research site
    Petach Tiqva, Israel
  • Research site
    Ramat Gan, Israel
  • Research site
    Tel Aviv, Israel
  • Research site
    Ancona, Italy
  • Research site
    Bologna, Italy
  • Research site
    Milano, Italy
  • Research site
    Napoli, Italy
  • Research site
    Roma, Italy
  • Research site
    Rozzano (Milano), Italy
  • Research site
    Chiba, Japan
  • Research site
    Ehime, Japan
  • Research site
    Hokkaido, Japan
  • Research site
    Koto-ku, Japan
  • Research site
    Nagoya, Japan
  • Research site
    Osaka, Japan
  • Research site
    Saitama, Japan
  • Research site
    Shizuoka, Japan
  • Research site
    Tochigi, Japan
  • Research site
    Tokyo, Japan
  • Research site
    Yokohama, Japan
  • Research site
    Anyang, Korea, Republic of
  • Research site
    Daegu, Korea, Republic of
  • Research site
    Inchon-si, Korea, Republic of
  • Research site
    Seongnam, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of

Showing the first 100 of 130 sites across 25 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Mar 2012 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2008
First posted
May 15, 2008
Start
Jun 2008
Primary completionActual
Mar 2012
CompletionActual
Feb 2013
Results first posted
May 16, 2013
Last update
Jul 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00678535
Responsible party
Sponsor
First posted
May 15, 2008
Start date
Jun 2008
Primary completion
Mar 2012
Completion
Feb 2013
Results posted
May 16, 2013
Last update
Jul 21, 2014

Study contacts

Florian Lordick, MD, PhD
principal investigator · University Clinic Leipzig, University Cancer Center Leipzig (UCCL), Leipzig Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion